P3 Health Partners (PIII) EBITDA (2021 - 2025)

P3 Health Partners has reported EBITDA for 5 years, with the latest figure at -$153.4 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 11.29% year-over-year to -$153.4 million; the trailing twelve-month figure through Dec 2025 stood at -$268.1 million (up 15.76% YoY), and the FY2025 full-year result was -$268.1 million, up 15.76% from the prior year.
• EBITDA for Q4 2025 stood at -$153.4 million, down from -$43.7 million in the prior quarter.
• The five-year high for EBITDA was $564.4 million in Q4 2021, with the low at -$911.6 million in Q2 2022.
• Historically, EBITDA has averaged -$90.6 million across 5 years, with a median of -$43.5 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA sank 3410.01% — and 2023, when it surged 97.76%.
• P3 Health Partners' EBITDA stood at $564.4 million in 2021, then slumped by 194.96% to -$535.9 million in 2022, then surged by 88.1% to -$63.8 million in 2023, then plunged by 116.13% to -$137.8 million in 2024, then declined by 11.29% to -$153.4 million in 2025.
• The last three EBITDA figures came in at -$153.4 million (Q4 2025), -$43.7 million (Q3 2025), and -$33.5 million (Q2 2025), per Business Quant data.